

INTRODUCTION

Delta-9-Tetrahydrocannabinol (THC) is one of the most effective antinociceptive agents used in the treatment of peripheral neuropathy. THC is highly lipophilic and susceptible to thermal and oxidative degradation. Identifying appropriate solvents in which THC is stable as well as adequately solubilized is crucial in developing various dosage forms. Lipid solvent systems are of utmost utility and relevance for formulating highly lipophilic drugs.

OBJECTIVES

- > To identify appropriate solid and liquid lipid excipients for development of THC dosage forms based on their solubilizing property.
- > To study the stability of THC in lipid excipients at different storage conditions. > To evaluate the effect of butylated hydroxytoluene and ascorbyl palmitate on
- stability of THC in lipid excipients at different storage conditions.

MATERIAL AND METHODS

- > Lipid vehicles listed in Table 1 and 2 were obtained from Gattefossé USA (Paramus, NJ). THC used for solubility studies were procured from Cayman Chemicals.
- > The solubility of THC in 9 different solid lipid excipients was qualitatively determined using a differential scanning calorimeter (DSC).
- > Different quantities (0, 250, 500, and 750 mg) of THC were taken into glass vials, and to these vials, excipients were added to make up the weight of the mixture to 1000 mg.
- Vials placed on hot plate-maintained at temperature slightly above the melting point of individual excipients for 15 to 20 min with constant stirring. Molten mixture transferred to DSC pans, sealed hermitically and placed for equilibration at room temperature for 24 h.
- > DSC analysis of samples was performed over the temperature range of 20 to 200 °C at 20 °C/min heating rate.
- > The solubility of THC in 19 different liquid lipid excipients was evaluated by the addition of excipients to tubes containing THC and vortexed for 15 min at room temperature.
- The samples were filtered and analyzed for THC content using HPLC.
- > The stability of THC with and without antioxidants (butylated hydroxytoluene) and ascorbyl palmitate) in the excipients were studied at 25 ± 2 °C and 4 ± 3 °C for 3 months.




Figure 1. The Change in Enthalpy of Fusion (measured by DSC) with increasing THC concentrations in solid excipients.

Solubility and Stability of Delta-9-Tetrahydrocannabinol in Lipid Excipients

Vijay Kumar Shankar¹, Abhishek Shettar¹, Praveen Kolimi¹, Inayet Ellis², Masumi Dave², Reena Murthy³, S. Narasimha Murthy¹ ¹Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USA ² Gattefossé USA, Paramus, NJ 07652, USA ³Topical Products Testing LLC, University, MS 38677, USA

Table 1 The solubility of	THC in solid lipid excipie	nts		
Excipients	· · · ·	ility in excipients (mg/g)	Table 3. The stability data of THC in lipid excipient at 25 °C \pm 2 °C / 60% RH a and without antioxidants for three-month (mean \pm SD) n=3.	nd 5 °C ± 3
Suppocire [®] AS2X		>500	3 Month THC assay (%)	
Suppocire [®] AM		>500	Lipid excipients 25 °C ± 2 °C / 60% RH 5 °	C ± 3 °C
Suppocire [®] D		>750	Without Without Without Without antioxidants antioxidants	Wit s antioxio
elucire [®] 48-16		>500	THC 69.7 ± 2.13 68.8 ± 1.57 80.8 ± 1.93	5 78.0 ±
elucire®43-01		>750	Labrasol [®] 96.0 ± 2.10 97.2 ± 0.73 99.7 ± 1.3	99.4 ±
elucire [®] 44-14		>250	Capryol [™] 90 94.9 ± 0.92 101 ± 2.27 96.8 ± 1.69	99.8 ±
elucire [®] 50-13		>500	Transcutol [®] HP 96.9 ± 2.66 99.5 ± 0.73 96.2 ± 1.67	' 99.5 ±
brafil [®] M 2130 CS		>750	Labrafac [™] Lipophile WL 1349 95.9 ± 0.31 98.9 ± 0.93 97.4 ± 1.00	5 96.7 ±
eleol™mono and digly	vcerides NF	>500	Labrafac™ MC 60 96.2 ± 3.32 97.7 ± 2.59 96.5 ± 2.25	
			Maisine [®] CC 98.0 ± 1.23 98.4 ± 0.63 99.4 ± 0.75	
•	IC in liquid lipid excipient		Peceol TM 88.0 ± 1.94 95.5 ± 1.49 92.4 ± 1.52	
Excipients	THC Solubility (mg/g) Mean ± SD (n=3)	THC Solubility (%) Mean ± SD (n=3)	Refined sesame oil 81.6 ± 4.56 83.4 ± 0.73 98.9 ± 0.92	
cutol®HP	434 ± 1.96	43.4 ± 0.20	Gelucire @44/14 93.7 ± 1.79 97.6 ± 0.37 94.4 ± 1.00	
d Soybean Oil IV	>500	>50	Geleol [™] mono & diglycerides 88.1 ± 2.43 91.0 ± 0.73 87.6 ± 1.33	
ed Sesame Oil IV	489 ± 6.95	48.9 ± 0.70		
ed Olive Oil IV	479 ± 4.29	47.9 ± 0.43		
[®] Oleique CC 497	>500	>50	Supposire® CM 87.9 ± 4.64 91.0 ± 1.47 89.3 ± 0.7	5 99.3 ±
[®] Diisostearique	>500	>50	RESULTS AND CONCLUSION	
	487 ± 2.96	48.7 ± 0.30		
ne® CC	>500	>50	The results demonstrated that the liquid and solid lipid excipients used in the THC freely and mitigate the degradation of THC significantly.	study cou
oglycol™ FCC	477 ± 12.0	47.7 ± 1.20	> THC in its neat form was poorly stable but when dissolved in lipid-based	excipients
oglycol™ 90	470 ± 5.08	47.0 ± 0.51	improved significantly.	
sol [®] ALF	422 ± 2.23	42.2 ± 0.22	> THC in lipid excipients was more stable at 5 ± 3 °C compared to samples store	
afil® M2125 CS	419 ± 2.76	41.9 ± 0.28	\succ The antioxidants used in the excipients, further improved the stability of THC \triangleright These excipients offer safe entions for further eral and topical formulation de	
fil® M1944 CS	454 ± 3.07	45.4 ± 0.31	These excipients offer safe options for further oral and topical formulation de	eiopment
fac™ PG	>500	>50	ACKNOWLEDGEMENT	
fac™ Lipophile WL	421 ± 3.38	42.1 ± 0.34		
yol™ PGMC	485 ± 14.7	48.5 ± 1.47	.55.	
yol™90	496 ± 5.21	49.6 ± 0.52	te t	
afac™ MC 60	496 ± 5.09	49.6 ± 0.51	Topical Products Testing LLC GAT 1	EFO

Table 1. The solubility of	^{THC} in solid lipic	d excipient	S
Excipients	TH	HC Solubili	ty in excipients (mg/g)
Suppocire [®] AS2X			>500
Suppocire®AM			>500
Suppocire [®] D			>750
Gelucire [®] 48-16			>500
Gelucire [®] 43-01			>750
Gelucire [®] 44-14			>250
Gelucire [®] 50-13			>500
Labrafil [®] M 2130 CS			>750
Geleol™mono and digly	ycerides NF		>500
able 2. The solubility of TH	IC in liquid linid e	excinients	
Excipients	THC Solubility		THC Solubility (%)
LACIPICITO	Mean ± SD		Mean ± SD (n=3)
ranscutol [®] HP	434 ± 1.9	96	43.4 ± 0.20
Refined Soybean Oil IV	>500		>50
efined Sesame Oil IV	489 ± 6.9	95	48.9 ± 0.70
efined Olive Oil IV	479 ± 4.2	29	47.9 ± 0.43
arol [®] Oleique CC 497	>500		>50
lurol [®] Diisostearique	>500		>50
eceol™	487 ± 2.9	96	48.7 ± 0.30
laisine [®] CC	>500		>50
auroglycol™ FCC	477 ± 12	2.0	47.7 ± 1.20
auroglycol™ 90	470 ± 5.0	08	47.0 ± 0.51
abrasol [®] ALF	422 ± 2.2	23	42.2 ± 0.22
abrafil [®] M2125 CS	419 ± 2.7	76	41.9 ± 0.28
abrafil [®] M1944 CS	454 ± 3.0	07	45.4 ± 0.31
abrafac™ PG	>500		>50
_abrafac™ Lipophile WL	421 ± 3.3	38	42.1 ± 0.34
Capryol™ PGMC	485 ± 14	4.7	48.5 ± 1.47
Capryol™90	496 ± 5.2	21	49.6 ± 0.52
Labrafac™ MC 60	496 ± 5.0	09	49.6 ± 0.51

Contact Information: Dr. S. Narasimha Murthy, <u>murthygroup@gmail.com</u>, Contact # 662-202-4929



ubilize



0

